Invasive procedures to biopsy tissue from cancer-tainted organs could be replaced by simply taking samples from a tiny “decoy” implanted just beneath the skin, University of Michigan researchers have demonstrated in mice.
These devices have a knack for attracting cancer cells traveling through the body. In fact, they can even pick up signs that cancer is preparing to spread, before cancer cells arrive.
“Biopsying an organ like the lung is a risky procedure that’s done only sparingly,” said Lonnie Shea, the William and Valerie Hall Chair of biomedical engineering at U-M. “We place these scaffolds right under the skin, so they’re readily accessible.”
The ease of access would also allow doctors to monitor the effectiveness of cancer treatments closer to real time.
The U-M team’s most recent work appears in Cancer Research, a publication of the American Association for Cancer Research.
Biopsies of the scaffold allowed researchers to analyze 635 genes present in the captured cancer cells. From these genes, the team identified ten that could predict whether a mouse was healthy, if it had a cancer that had not begun to spread yet, or if a cancer was present and had begun to spread. They could do that all without the need for an invasive biopsy of an organ.
The gene expression obtained at the scaffold had distinct patterns relative to cells from the blood, which are obtained through a technique known as liquid biopsy. These differences highlight that the tissue in these traps provides unique information that correlates with disease progression.
The researchers have demonstrated that the synthetic scaffolds work with multiple types of cancers in mice, including pancreatic cancer. They work by luring immune cells, which, in turn, attract cancer cells.
“When we started off, the idea was that we would biopsy the scaffold and look for tumor cells that had followed the immune cells there,” Shea said. “But we realized that by analyzing the immune cells that gather first, we can detect the cancer before it’s spreading.”
In treating cancer, early detection is key.
“Currently, early signs of metastasis can be difficult to detect,” said Jacqueline Jeruss, an associate professor of surgery and biomedical engineering and a co-author of the study. “Imaging may be done once a patient experiences symptoms, but that implies the number of cancer cells may already be substantial. Improved detection methods are needed to identify metastasis at a point when targeted treatments can have a significant beneficial impact on slowing disease progression.”
The immune cells allowed researchers to identify whether treatments were effective in the mice and which subjects were sensitive or resistant to treatment.
The decoy’s ability to draw immune and cancer cells can also bolster the treatment itself. In previous research, the devices demonstrated an ability to slow the growth of metastatic breast cancer tumors in mice, by reducing the number of cancer cells that can reach those tumors.
In the future, Shea envisions that the scaffolds could be outfitted with sensors and Bluetooth technology that could deliver information in real time without the need for a biopsy.
The Latest on: Biopsies
via Google News
The Latest on: Biopsies
- FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung Canceron August 7, 2020 at 2:29 pm
The FDA on Friday approved the Guardant360 CDx assay to identify metastatic lung cancer patients who carry specific EGFR mutations, making them eligible for upfront treatment with osimertinib ...
- Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2020 Results - Earnings Call Transcripton August 5, 2020 at 11:18 am
Q2 2020 Earnings Conference Call August 05, 2020, 08:30 AM ET Company Participants Gerard Michel - CFO Nick Colangelo - President and CEO Conference Call Participants Ryan Zimmerman - BTIG Danielle ...
- Liquid Biopsies Generate Ample Insights from Sparse Clueson August 3, 2020 at 8:04 am
New liquid biopsy tools such as target enrichment and duplex sequencing can help investigators derive meaning from the subtly variable DNA fragments shed in trace amounts by healthy and diseased ...
- Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platformon August 3, 2020 at 5:32 am
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes ...
- AI diagnoses prostate cancer with 98% accuracyon July 30, 2020 at 11:16 am
When tested on 1,600 biopsies from 100 suspected patients, the model picked up on the cancer cases 98% of the time. “Algorithms like this are especially useful in lesions that are atypical,” said ...
- Prostate Biopsies Device Market By Development, Trends, Investigation 2020 And Forecast To 2026on July 24, 2020 at 4:48 am
Jul 24, 2020 (Profound via COMTEX) -- A recent report provides crucial insights along with application based and forecast information in the Global Prostate Biopsies Device Market. The report ...
- Google AI outperforms general pathologists at validating Gleason grading of prostate cancer biopsieson July 23, 2020 at 5:00 pm
A team of researchers from Google Health, working with others from institutions across the U.S. and Canada has found that a Google AI system was able to outperform general pathologists when ...
- Half of Recommended Biopsies Can Detect Microscopic Colitison July 14, 2020 at 4:59 pm
"Endoscopists therefore often collect multiple random colonic biopsies, potentially oversampling, increasing times of colonoscopy and slide review," Dr. Virine and his associates wrote.
- Robotic Biopsies Help Increase Lung Cancer Survival Rateson July 13, 2020 at 5:09 am
Texas Health Harris Methodist in Fort Worth has become the first hospital in North Texas to use a robotic-assisted technology called Ion to biopsy potential tumors earlier than traditional ...
via Bing News